News

Published on 2 Nov 2022 on Zacks via Yahoo Finance

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates


Article preview image

Glaukos (GKOS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 15.09%. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.44 per share when it actually produced a loss of $0.83, delivering a surprise of -88.64%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

NYSE.GKOS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio

Glaukos Corporation GKOS is well-poised for growth in the coming quarters, courtesy of its favora...

Zacks via Yahoo Finance 28 Dec 2022

Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Glaukos (GKOS). Shares have added about 0....

Zacks via Yahoo Finance 2 Dec 2022

Despite currently being unprofitable, Glaukos (NYSE:GKOS) has delivered a 79% return to shareholders...

Glaukos Corporation (NYSE:GKOS) shareholders have seen the share price descend 16% over the month...

Simply Wall St. via Yahoo Finance 26 Nov 2022

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos Corporation GKOS is well-poised for growth, backed by favorable clinical trial results an...

Zacks via Yahoo Finance 23 Nov 2022

Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View

Glaukos Corporation GKOS reported an adjusted loss per share of 45 cents for the third quarter of...

Zacks via Yahoo Finance 3 Nov 2022

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estim...

Zacks via Yahoo Finance 2 Nov 2022

The Zacks Analyst Blog Highlights Nevro, Masimo, Abiomed and Glaukos

For Immediate Release Chicago, IL – October 28, 2022 – Zacks.com announces the list of stocks fea...

Zacks via Yahoo Finance 28 Oct 2022

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Wall Street expects a year-over-year decline in earnings on lower revenues when Glaukos (GKOS) re...

Zacks via Yahoo Finance 26 Oct 2022

Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday By Benzinga

Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday

Investing.com 8 Sep 2022

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

Glaukos Corporation GKOS announced positive top-line data from two pivotal studies evaluating its...

Zacks via Yahoo Finance 8 Sep 2022